Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Susan Bobulsky sold 1,875 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $32.00, for a total value of $60,000.00. Following the completion of the transaction, the insider directly owned 387,475 shares of the company’s stock, valued at approximately $12,399,200. This represents a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Susan Bobulsky also recently made the following trade(s):
- On Tuesday, October 6th, Susan Bobulsky sold 6,444 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $30.00, for a total transaction of $193,320.00.
- On Tuesday, September 15th, Susan Bobulsky sold 1,195 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $27.00, for a total transaction of $32,265.00.
Adaptive Biotechnologies Stock Down 1.5%
Adaptive Biotechnologies stock traded down $0.44 during trading hours on Friday, hitting $29.04. The stock had a trading volume of 2,063,725 shares, compared to its average volume of 2,197,728. The stock’s 50-day moving average price is $26.91 and its 200-day moving average price is $20.13. The stock has a market capitalization of $4.70 billion, a P/E ratio of -64.53 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 12-month low of $12.00 and a 12-month high of $32.21. The company has a quick ratio of 3.87, a current ratio of 3.97 and a debt-to-equity ratio of 1.82.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.12. The firm had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $71.57 million. Adaptive Biotechnologies had a negative net margin of 23.67% and a negative return on equity of 23.95%. The business’s revenue for the quarter was down 10.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.06 earnings per share. Equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.24 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts have commented on ADPT shares. TD Cowen lifted their target price on Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. BTIG Research boosted their price target on Adaptive Biotechnologies from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Tuesday, September 22nd. The Goldman Sachs Group initiated coverage on Adaptive Biotechnologies in a report on Tuesday, September 29th. They set a “buy” rating and a $35.00 price target on the stock. Guggenheim increased their price objective on Adaptive Biotechnologies from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Tuesday, November 10th. Finally, National Bank Financial set a $34.00 price objective on Adaptive Biotechnologies in a report on Tuesday, September 22nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average target price of $30.31.
View Our Latest Report on Adaptive Biotechnologies
Institutional Investors Weigh In On Adaptive Biotechnologies
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Adaptive Biotechnologies during the 2nd quarter valued at $324,735,000. Wellington Management Group LLP grew its holdings in shares of Adaptive Biotechnologies by 53.2% in the second quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock worth $126,799,000 after acquiring an additional 2,053,944 shares during the period. Bank of America Corp DE bought a new stake in shares of Adaptive Biotechnologies in the second quarter worth $37,109,000. Principal Financial Group Inc. grew its holdings in shares of Adaptive Biotechnologies by 9.8% in the first quarter. Principal Financial Group Inc. now owns 1,704,887 shares of the company’s stock worth $23,664,000 after acquiring an additional 152,378 shares during the period. Finally, Freestone Grove Partners LP purchased a new stake in Adaptive Biotechnologies during the second quarter valued at $18,912,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.
About Adaptive Biotechnologies
Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.
Read More
- Five stocks we like better than Adaptive Biotechnologies
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
